

DAFTAR PUSTAKA

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA. Cancer J. Clin.*, vol. 68, no. 6, pp. 394–424, 2018, doi: 10.3322/caac.21492.
- [2] X. Wang *et al.*, "Proton Radiotherapy for Liver Tumors: Dosimetric Advantages Over Photon Plans," *Med. Dosim.*, vol. 33, no. 4, pp. 259–267, 2008, doi: 10.1016/j.meddos.2007.04.008.
- [3] M. Chuong, A. Kaiser, J. Molitoris, A. M. Romero, and S. Apisarnthanarax, "Proton beam therapy for liver cancers," *J. Gastrointest. Oncol.*, vol. 11, no. 1, pp. 157–165, 2020, doi: 10.21037/jgo.2019.04.02.
- [4] M. Suzuki, "Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era," *Int. J. Clin. Oncol.*, vol. 25, no. 1, pp. 43–50, 2020, doi: 10.1007/s10147-019-01480-4.
- [5] W. Wiyanti, "Pertama di Asia Tenggara, RI Akan Punya Proton Beam Therapy untuk Kanker," *Health.detik.com*, 2018. <https://health.detik.com/berita-detikhealth/d-4272571/pertama-di-asia-tenggara-ri-akan-punya-proton-beam-therapy-untuk-kanker> (accessed Oct. 20, 2020).
- [6] Z. Ahmadi Ganjeh, M. Eslami-Kalantari, and A. A. Mowlavi, "Dosimetry calculations of involved and noninvolved organs in proton therapy of liver cancer: a simulation study," *Nucl. Sci. Tech.*, vol. 30, no. 12, pp. 1–7, 2019, doi: 10.1007/s41365-019-0698-8.
- [7] World Health Organization, "Cancer," 2018. <https://www.who.int/news-room/fact-sheets/detail/cancer> (accessed Aug. 04, 2020).
- [8] J. Liz and M. Esteller, "lncRNAs and microRNAs with a role in cancer development," *Biochim. Biophys. Acta - Gene Regul. Mech.*, vol. 1859, no. 1, pp. 169–176, 2016, doi: 10.1016/j.bbagr.2015.06.015.
- [9] J. Hopkins, "Liver: Anatomy and Functions," 2020. <https://www.hopkinsmedicine.org/health/conditions-and-diseases/liver-anatomy-and-functions> (accessed Aug. 04, 2020).
- [10] A. Potapova, V. Iakovleva, A. B. L. Ong, L. Zender, and T. Wuestefeld, "THU-486-A pro-regenerative environment triggers premalignant to malignant transformation and pinpoints new therapeutic targets," *J. Hepatol.*, vol. 70, no. 1, p. e375, Apr. 2019, doi: 10.1016/S0618-8278(19)30733-9.
- [11] M. S. Ahmad, N. Suardi, A. S. Mustapa, H. Mohammad, A. A. Oglat, and

- M. Bassam, "Current Status Regarding the Tumour Of HCC : A Literature Review," *J. Gastroenterol. Hepatol. Res.*, vol. 8, no. 2, pp. 2841–2852, 2019, doi: 10.17554/j.issn.2224-3992.2019.08.814.
- [12] D. Sia, A. Villanueva, S. L. Friedman, and J. M. Llovet, "Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis," *Gastroenterology*, vol. 152, no. 4, pp. 745–761, 2017, doi: 10.1053/j.gastro.2016.11.048.
- [13] A. B. Ryerson *et al.*, "Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer," *Cancer*, vol. 122, no. 9, pp. 1312–1337, 2016, doi: 10.1002/cncr.29936.
- [14] S. Affo, L.-X. Yu, and R. F. Schwabe, "The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer," *Annu. Rev. Pathol. Mech. Dis.*, vol. 12, no. 1, pp. 153–186, Jan. 2017, doi: 10.1146/annurev-pathol-052016-100322.
- [15] A. Marengo, C. Rosso, and E. Bugianesi, "Liver cancer: Connections with obesity, fatty liver, and cirrhosis," *Annu. Rev. Med.*, vol. 67, no. September 2015, pp. 103–117, 2016, doi: 10.1146/annurev-med-090514-013832.
- [16] D. A. Kelly, *Liver Diseases*. Cham: Springer International Publishing, 2020.
- [17] N. Fukumitsu, T. Okumura, and H. Sakurai, "Radiotherapy for liver cancer," *J. Gen. Fam. Med.*, vol. 18, no. 3, pp. 126–130, 2017, doi: 10.1002/jgf2.19.
- [18] M. Reig, L. G. da Fonseca, and S. Faivre, "New trials and results in systemic treatment of HCC," *J. Hepatol.*, vol. 69, no. 2, pp. 525–533, 2018, doi: 10.1016/j.jhep.2018.03.028.
- [19] American Society of Clinical Oncology, "Understanding Radiation Therapy," *Cancer.net*, 2018. <https://www.cancer.net/navigating-cancer-care/how-cancer-treated/radiation-therapy/understanding-radiation-therapy> (accessed Aug. 04, 2020).
- [20] H. Igaki, M. Mizumoto, T. Okumura, K. Hasegawa, N. Kokudo, and H. Sakurai, "A systematic review of publications on charged particle therapy for hepatocellular carcinoma," *Int. J. Clin. Oncol.*, vol. 23, no. 3, pp. 423–433, 2018, doi: 10.1007/s10147-017-1190-2.
- [21] H. Mirzaei *et al.*, "Boron neutron capture therapy: Moving toward targeted cancer therapy," *J. Cancer Res. Ther.*, vol. 12, no. 2, pp. 520–525, 2016, doi: 10.4103/0973-1482.176167.
- [22] Badan Pengawas Tenaga Nuklir, "Peraturan Kepala Badan Pengawas Tenaga Nuklir Nomor 3 Tahun 2013 Tentang Keselamatan Radiasi dalam Penggunaan Radioterapi." Badan Pengawas Tenaga Nuklir, Jakarta, 2013, [Online]. Available: <https://jdih.bapeten.go.id/unggah/dokumen/peraturan/228-full.pdf>.

- [23] T. I. Marshall *et al.*, “Investigating the Implications of a Variable RBE on Proton Dose Fractionation Across a Clinical Pencil Beam Scanned Spread-Out Bragg Peak,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 95, no. 1, pp. 70–77, 2016, doi: 10.1016/j.ijrobp.2016.02.029.
- [24] B. Gottschalk, “Techniques of Proton Radiotherapy (04) Basics.” Harvard University, 2011, [Online]. Available: [https://gray.mgh.harvard.edu/attachments/article/337/Techniques of Proton Radiotherapy \(04\) Basics.pdf](https://gray.mgh.harvard.edu/attachments/article/337/Techniques%20of%20Proton%20Radiotherapy%20(04)%20Basics.pdf).
- [25] ICRP, *The 2007 Recommendations of the International Commission on Radiological Protection*, vol. 37, no. 2–4. 2007.
- [26] C. Rangacharyulu, *Physics of Nuclear Radiations - Concepts, Techniques and Applications*. 2014.
- [27] M. S. Stecker *et al.*, “Guidelines for Patient Radiation Dose Management,” *J. Vasc. Interv. Radiol.*, vol. 20, no. 7 SUPPL., pp. S263–S273, 2009, doi: 10.1016/j.jvir.2009.04.037.
- [28] W. Jaschke, M. Schmuth, A. Trianni, and G. Bartal, “Radiation-Induced Skin Injuries to Patients: What the Interventional Radiologist Needs to Know,” *Cardiovasc. Intervent. Radiol.*, vol. 40, no. 8, pp. 1131–1140, 2017, doi: 10.1007/s00270-017-1674-5.
- [29] J. Kim and Y. Jung, “Radiation-induced liver disease: Current understanding and future perspectives,” *Exp. Mol. Med.*, vol. 49, no. 7, pp. e359-9, 2017, doi: 10.1038/emmm.2017.85.
- [30] L. A. Dawson and R. K. Ten Haken, “Partial Volume Tolerance of the Liver to Radiation,” *Semin. Radiat. Oncol.*, vol. 15, no. 4, pp. 279–283, Oct. 2005, doi: 10.1016/j.semradonc.2005.04.005.
- [31] B. Emami *et al.*, “Tolerance of normal tissue to therapeutic irradiation,” *Int. J. Radiat. Oncol.*, vol. 21, no. 1, pp. 109–122, May 1991, doi: 10.1016/0360-3016(91)90171-Y.
- [32] P. Rubin, “Law and Order of Radiation Sensitivity,” in *Radiation Tolerance of Normal Tissues*, J. M. Vaeth and J. L. Meyer, Eds. Basel: Karger, 1989, pp. 7–40.
- [33] ICRU, “1 INTRODUCTION,” *J. ICRU*, vol. 7, no. 2, pp. 11–20, Dec. 2007, doi: 10.1093/jicru/ndm024.
- [34] ICRU, “2 RADIATION BIOLOGY CONSIDERATIONS,” *J. ICRU*, vol. 7, no. 2, pp. 21–28, Dec. 2007, doi: 10.1093/jicru/ndm025.
- [35] R. Mohan, C. R. Peeler, F. Guan, L. Bronk, W. Cao, and D. R. Grosshans, “Radiobiological issues in proton therapy,” *Acta Oncol. (Madr.)*, vol. 56, no. 11, pp. 1367–1373, 2017, doi: 10.1080/0284186X.2017.1348621.
- [36] Y. Chen, C. Grassberger, J. Li, T. S. Hong, and H. Paganetti, “Impact of

- potentially variable RBE in liver proton therapy,” *Phys. Med. Biol.*, vol. 63, no. 19, p. 195001, 2018, doi: 10.1088/1361-6560/aadf24.
- [37] W. D. Newhauser and R. Zhang, “The physics of proton therapy,” *Phys. Med. Biol.*, vol. 60, no. 8, p. R155, 2015.
- [38] D. H. Kim *et al.*, “Proton range verification in inhomogeneous tissue: Treatment planning system vs. measurement vs. Monte Carlo simulation,” *PLoS One*, vol. 13, no. 3, p. e0193904, 2018, doi: 10.1371/journal.pone.0193904.
- [39] M. Chuong *et al.*, “Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer,” *J. Gastrointest. Oncol.*, vol. 9, no. 4, pp. 687–693, 2018, doi: 10.21037/jgo.2018.03.14.
- [40] Z. Li and R. Slopsema, “Beam Delivery Techniques : Passive Scattering Proton Beams,” 2010. [Online]. Available: http://www.ptcog.ch/archive/conference_p&t&v/PTCOG49/presentationsEW/17-2-2_passive.pdf.
- [41] R. Mohan and D. Grosshans, “Proton therapy - present and future,” *Adv. Drug Deliv. Rev.*, vol. 109, pp. 26–44, 2017.
- [42] G. Mondlane, A. Ureba, M. Gubanski, P. A. Lind, and A. Siegbahn, “Estimation of the risk for radiation-induced liver disease following photon-or proton-beam radiosurgery of liver metastases,” *Radiat. Oncol.*, vol. 13, no. 1, p. 206, 2018, doi: 10.1186/s13014-018-1151-6.
- [43] Y. Oshiro *et al.*, “Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma,” *Radiother. Oncol.*, vol. 123, no. 2, pp. 240–245, 2017.
- [44] M. Mizumoto *et al.*, “Proton beam therapy for hepatocellular carcinoma: A comparison of three treatment protocols,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 81, no. 4, pp. 1039–1045, 2011, doi: 10.1016/j.ijrobp.2010.07.015.
- [45] A. Wambersie, P. Andreo, P. M. Deluca, R. Gahbauer, and J. H. Hendry, “Biological weighting of absorbed doses in proton and heavier ion - beam therapy : ICRU - IAEA recommendations on the isoeffect - dose concept,” 2009. [Online]. Available: [https://videosever1.iaea.org/media/HHW/Radiotherapy/ICARO_proceedings/Presentation_slides/Wednesday/2 IAEA/1 morning/s13b/s13b-wambersie.pdf](https://videosever1.iaea.org/media/HHW/Radiotherapy/ICARO_proceedings/Presentation_slides/Wednesday/2%20IAEA/1%20morning/s13b/s13b-wambersie.pdf).
- [46] F. Albertini, “Treatment planning for scanned proton beams and IMPT,” 2010. [Online]. Available: http://www.ptcog.ch/archive/conference_p&t&v/PTCOG49/presentationsEW/18-2-2_TPS-scanning.pdf.
- [47] R. F. Barth, P. Mi, and W. Yang, “Boron delivery agents for neutron capture therapy of cancer,” *Cancer Commun.*, vol. 38, no. 1, pp. 1–15, 2018, doi:

10.1186/s40880-018-0299-7.

- [48] R. F. Barth, Z. Zhang, and T. Liu, "A realistic appraisal of boron neutron capture therapy as a cancer treatment modality," *Cancer Commun. (London, England)*, vol. 38, no. 1, p. 36, 2018, doi: 10.1186/s40880-018-0280-5.
- [49] Y. H. Hung *et al.*, "Therapeutic efficacy and radiobiological effects of boric acid-mediated BNCT in a VX2 multifocal liver tumor-bearing rabbit model," *Anticancer Res.*, vol. 39, no. 10, pp. 5495–5504, 2019, doi: 10.21873/anticancer.13742.
- [50] K. Nedunchezian, N. Aswath, M. Thiruppathy, and S. Thirugnanamurthy, "Boron neutron capture therapy - a literature review," *J. Clin. Diagnostic Res.*, vol. 10, no. 12, pp. ZE01–ZE04, 2016, doi: 10.7860/JCDR/2016/19890.9024.
- [51] Stella Pharma, "About BNCT." <https://stella-pharma.co.jp/en/about-bnct> (accessed Sep. 10, 2020).
- [52] C. Y. Wu *et al.*, "Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT)," *Colloids Surfaces B Biointerfaces*, vol. 183, no. August, p. 110387, 2019, doi: 10.1016/j.colsurfb.2019.110387.
- [53] M. A. Garabalino *et al.*, "Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model," *Radiat. Environ. Biophys.*, vol. 58, no. 3, pp. 455–467, 2019, doi: 10.1007/s00411-019-00796-z.
- [54] Z. Ahmadi Ganjeh and M. Eslami-Kalantari, "Design and optimization of two-sided beam based on ${}^7\text{Li}(p,n){}^7\text{Be}$ source using in BNCT for brain and liver tumors," *Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip.*, vol. 916, no. November 2018, pp. 290–295, 2019, doi: 10.1016/j.nima.2018.11.084.
- [55] Y. Kasesaz and M. Karimi, "A novel design of beam shaping assembly to use D-T neutron generator for BNCT," *Appl. Radiat. Isot.*, vol. 118, pp. 317–325, Dec. 2016, doi: 10.1016/j.apradiso.2016.09.029.
- [56] H. W. Koay, T. Shima, M. Fukuda, H. Kanda, S. Hara, and T. Yorita, "Experimental study of fast-neutron production and moderation for accelerator-based BNCT system," *Appl. Radiat. Isot.*, vol. 152, no. November 2018, pp. 11–17, 2019, doi: 10.1016/j.apradiso.2019.06.002.
- [57] H. Koivunoro, D. L. Bleuel, U. Nastasi, T. P. Lou, J. Reijonen, and K. N. Leung, "BNCT dose distribution in liver with epithermal D-D and D-T fusion-based neutron beams," *Appl. Radiat. Isot.*, vol. 61, no. 5, pp. 853–859, 2004, doi: 10.1016/j.apradiso.2004.05.043.
- [58] J. G. Fantidis and G. Nicolaou, "Optimization of Beam Shaping Assembly

design for Boron Neutron Capture Therapy based on a transportable proton accelerator,” *Alexandria Eng. J.*, vol. 57, no. 4, pp. 2333–2342, 2018, doi: 10.1016/j.aej.2017.08.004.

- [59] H. W. Koay, M. Fukuda, H. Toki, R. Seki, H. Kanda, and T. Yorita, “Feasibility study of compact accelerator-based neutron generator for multi-port BNCT system,” *Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip.*, vol. 899, pp. 65–72, 2018, doi: 10.1016/j.nima.2018.05.025.
- [60] T. Sato *et al.*, “Features of Particle and Heavy Ion Transport code System (PHITS) version 3.02,” *J. Nucl. Sci. Technol.*, vol. 55, no. 6, pp. 684–690, 2018, doi: 10.1080/00223131.2017.1419890.
- [61] W. Kleeven, “IBA Proton Therapy Systems - Accelerators, beamlines and gantry technology.” 2017, [Online]. Available: http://www.bvsabr.be/js/tiny_mce/plugins/moxiemanager/data/files/20170626/IBA_WKleeven.pdf.
- [62] J. Van De Walle, “IBA accelerators for proton and ion beam therapy,” Birmingham, 2016.
- [63] S. Henrotin *et al.*, “Commissioning and testing of the first IBA S2C2,” in *Proc. 21st Int. Conf. on Cyclotrons and Their Applications (Cyclotrons - 16)(Zurich, Switzerland, 11 - 16 September 2016)*, 2016, pp. 178–180.
- [64] M. Cristy and K. F. Eckerman, “Specific Absorbed Fractions of Energy at Various Ages from Internal Photons Sources,” *Oak Ridge, TN Oak Ridge Natl. Lab.*, pp. V1–V7. ORNL/TM-8381, 1987, doi: 10.2172/6263443.
- [65] J. Valentin, “Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89,” *Ann. ICRP*, vol. 32, no. 3–4, pp. 1–277, 2002.
- [66] M. Suzuki, Y. Sakurai, S. Masunaga, Y. Kinashi, K. Nagata, and K. Ono, “Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors,” *Int. J. Radiat. Oncol.*, vol. 58, no. 3, pp. 892–896, Mar. 2004, doi: 10.1016/j.ijrobp.2003.09.084.